Hypertension, RAAS blockade and risk in COVID-19 patients
SARS-coronavirus 2 (SARS-CoV-2) enters the host-cells by binding the transmembraneous angiotensin converting enzyme 2 (ACE2) when causing coronavirus disease 2019 (COVID-19). The role of angiotensin converting enzyme inhibitors (ACE) and angiotensin II receptor blockers (ARB) in COVID-19 is debated. Several well-conducted observational studies show no increased risk from RAAS blockade in COVID-19 patients and are detailed in this brief review. The Swedish Society of Hypertension, Stroke and Vascular Medicine supports current recommendations that ongoing RAAS blockade should be maintained in patients with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Lakartidningen - 117(2020) vom: 23. Juni |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
Pågående RAAS-blockad bör behållas vid covid-19 |
|---|
| Beteiligte Personen: |
Spaak, Jonas [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 07.07.2020 Date Revised 18.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM311726070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311726070 | ||
| 003 | DE-627 | ||
| 005 | 20231225142857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311726070 | ||
| 035 | |a (NLM)32594472 | ||
| 035 | |a (PII)20102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Spaak, Jonas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertension, RAAS blockade and risk in COVID-19 patients |
| 246 | 3 | 3 | |a Pågående RAAS-blockad bör behållas vid covid-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SARS-coronavirus 2 (SARS-CoV-2) enters the host-cells by binding the transmembraneous angiotensin converting enzyme 2 (ACE2) when causing coronavirus disease 2019 (COVID-19). The role of angiotensin converting enzyme inhibitors (ACE) and angiotensin II receptor blockers (ARB) in COVID-19 is debated. Several well-conducted observational studies show no increased risk from RAAS blockade in COVID-19 patients and are detailed in this brief review. The Swedish Society of Hypertension, Stroke and Vascular Medicine supports current recommendations that ongoing RAAS blockade should be maintained in patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Kahan, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 117(2020) vom: 23. Juni |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2020 |g day:23 |g month:06 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2020 |b 23 |c 06 | ||